Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Metastatic ALK+ Non Small Cell Lung Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 10 of 0 results

Early research (Phase 1)Study completedNCT02442414
What this trial is testing

KBP-5209 in Patients With Advanced Solid Tumors

Who this might be right for
Advanced Solid Tumors
Sihuan Pharmaceutical Holdings Group Ltd. 35
Post-approval studies (Phase 4)Active Not RecruitingNCT06282874
What this trial is testing

Lorlatinib in Patients With ALK-Positive NSCLC With Brain or Leptomeningeal Metastases

Who this might be right for
Carcinoma, Non-Small-Cell LungBrain MetastasesLeptomeningeal Metastasis
Guangdong Association of Clinical Trials 41
Testing effectiveness (Phase 2)Active Not RecruitingNCT06007937
What this trial is testing

Lorlatinib in Combination With Ramucirumab in People With Lung Cancer

Who this might be right for
Non Small Cell Lung CancerMetastaticRecurrent
Memorial Sloan Kettering Cancer Center 9
Testing effectiveness (Phase 2)Looking for participantsNCT07360743
What this trial is testing

Immunotherapy Without Chemotherapy for Advanced Lung Cancer Patients With High PD-L1 Levels

Who this might be right for
Non Small Cell Lung Cancer (Squamous or Non Squamous)
UNICANCER 275
Large-scale testing (Phase 3)Study completedNCT02352948
What this trial is testing

A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer

Who this might be right for
Non - Small Cell Lung Cancer NSCLC
AstraZeneca 597
Testing effectiveness (Phase 2)Study completedNCT04111705
What this trial is testing

Lorlatinib After Failure of First-line Second-generation ALK Kinase Inhibitor in Patients With Advanced ALK-positive Non-small Cell Lung Cancer

Who this might be right for
Non Small Cell Lung Cancer Metastatic
Intergroupe Francophone de Cancerologie Thoracique 23
Early research (Phase 1)Active Not RecruitingNCT03611738
What this trial is testing

Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC

Who this might be right for
Non-small Cell Lung CancerLung CancerNon-small Cell Lung Cancer Metastatic+3 more
H. Lee Moffitt Cancer Center and Research Institute 21
Early research (Phase 1)Ended earlyNCT04849273
What this trial is testing

TPX-0131, a Novel Oral ALK Tyrosine Kinase Inhibitor, in Patients With ALK+ Advanced or Metastatic NSCLC

Who this might be right for
Non Small Cell Lung CancerNon-Small Cell Lung CancerNSCLC+3 more
Turning Point Therapeutics, Inc. 11
Early research (Phase 1)Active Not RecruitingNCT04837716
What this trial is testing

Ensartinib, Carboplatin, Pemetrexed and Bevacizumab for the Treatment of Stage IIIC or IV or Recurrent ALK-Positive Non-small Cell Lung Cancer

Who this might be right for
Metastatic Lung Non-Small Cell CarcinomaRecurrent Lung Non-Small Cell CarcinomaStage IIIC Lung Cancer AJCC v8+3 more
M.D. Anderson Cancer Center 12
Early research (Phase 1)Active Not RecruitingNCT04227028
What this trial is testing

Brigatinib and Bevacizumab for the Treatment of ALK-Rearranged Locally Advanced, Metastatic, or Recurrent NSCLC

Who this might be right for
Locally Advanced Lung Non-Small Cell CarcinomaMetastatic Lung Non-Small Cell CarcinomaRecurrent Lung Non-Small Cell Carcinoma+7 more
City of Hope Medical Center 5